No Data
Jiuzhou Pharma Gets Nod to Market Vortioxetine Hydrobromide
Zhejiang Jiuzhou Pharmaceutical (603456.SH): A cumulative repurchase of 0.81% of shares.
On May 6, Gelonghui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that as of April 30, 2025, the company has repurchased a total of 7.2521 million shares through centralized trading, accounting for 0.81% of the company's total share capital. The highest transaction price was 13.85 yuan per share, the lowest was 12.36 yuan per share, and the total amount paid was 95.2771 million yuan (excluding transaction fees).
Overview of the lifting of restrictions on share sales of A-shares | April 29
According to Zhito Finance APP, on April 29, a total of 10 listed companies had their restricted shares released, with a total market value of approximately 6.016 billion yuan. The specific details of the restricted stock release today are as follows: Stock Abbreviation Stock Code Type of Restricted Shares Number of Released Shares Zhejiang Jiuzhou Pharmaceutical 603456 Stock-based Incentive 0.4809 million Shenzhen Soling Industrial 002766 Stock-based Incentive 3.31 million Jiang Su Suyan Jingshen 603299 Stock-based Incentive 3.3273 million Hunan Oil Pump 603319 Stock-based Incentive 0.3269 million Yunnan Jianzhijia Health-Chain 605266 Additional A Share Legal Person Allocation 11.5152 million National Energy Sun.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The approval notice for the market launch application of Fumarate Vonoprazan as a Chemical Raw Materials has been received.
Gelonghui, April 24丨Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd. has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration for Fumaric Acid Vorinostat. Fumaric Acid Vorinostat is primarily used to treat acid-related diseases, including reflux esophagitis (RE), gastric ulcers, and duodenal ulcers.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The holding subsidiary has obtained the Pharmaceutical registration certificate.
On April 22, Gelonghui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its holding subsidiary, Zhejiang Jiuzhou Biomedical Co., Ltd. (referred to as "Jiuzhou Biomedical"), received the pharmaceutical registration certificate for Lacosamide Tablets issued by the National Medical Products Administration. Lacosamide Tablets are suitable for adjunctive treatment of partial seizures in epilepsy patients aged 4 years and older. Obtaining the pharmaceutical registration certificate for Lacosamide Tablets further enriches the company's product pipeline and helps enhance the market competitiveness of the company's products. The above matters will not have a significant impact on the company's performance in the short term.
Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Soft Earnings Don't Show The Whole Picture
Those Who Invested in Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Five Years Ago Are up 174%
